INTRODUCTION
============

The recent use of culture-independent microbiological techniques based on deep-sequencing has shown that the respiratory tract of healthy people are not sterile as formerly thought, but composed of a previously unappreciated complex microbial community referred as the microbiome ([@B12]; [@B31]). In particular, two international projects were recently launched: the American Human Microbiome Project (HMP)^[1](#fn01){ref-type="fn"}^ and the European Metagenomics of the Human Intestinal Tract (MetaHit^[2](#fn02){ref-type="fn"}^; [@B84]; [@B51]). They first aimed to characterize the nature, composition, and diversity of normal and pathological bacteriomes (bacterial microbiomes) at different body sites including the nasal passages, oral cavities, skin, gastrointestinal tract, and urogenital tract. The respiratory tract was secondarily included in the American program as a body site, and the lung microbiome has become a new attractive and rapidly growing field of research. However, the majority of these lung microbiome studies have focused on bacteria; the characterization of viral or fungal microbiomes---also referred as the virome and mycobiome---has not been closely investigated. It is commonly accepted that a given microbial community associated with host tissues or organs is known as the "biota," while the whole genome collection of this microbial community is mentioned as the "biome." Accordingly, "mycobiota" refers to the fungal component of a given microbial community, and the corresponding genomes are referred to as the "mycobiome" ([@B45]; [@B53]; [@B71]).

While the concept of the human mycobiome has been emphasized in the past few years ([@B19]; [@B49]), little is known about the human mycobiome in general, and the lung mycobiome in particular as confirmed by our search in PubMed of the terms: "mycobiota," "mycobiome," "human mycobiota," "human mycobiome," "mycobiome AND lungs," "mycobiota AND lungs," "human mycobiome AND lungs," "human microbiota and lungs," "fungal microbiome AND lungs" that appeared respectively in 190, 29, 49, 24, 272, 1, 188, 213, and 146 publications. With or without using these specific keywords, a total of 67 research publications and 29 reviews were relevant to the purpose of our review. Lung mycobiome research is clearly an "emerging world" as recently proposed ([@B49]), for which the growing scientific interest is supported by several reasons.

First, the human respiratory tract represents the main portal of entry for numerous microorganisms primarily those occurring as airborne particles such as viruses, bacteria, or fungi. Fungal spores are representing more than 50,000 spores per cubic meter of air during the fungal season ([@B73]; [@B24]). The corresponding microorganism characteristics, coupled with the local immune response will determine whether they will be cleared or adhere to and colonize the respiratory tract, leading to pulmonary diseases (or their infectious complications). Although the total number of fungal cells is smaller than that of the bacteria, nobody is fungus-free ([@B49]).

Second, mycosis represents an emergent threat to public health, which has increased not only in width, but also in depth. Whereas fungal pulmonary infections represent life-threatening diseases in patients in a comparable rate to the mortality attributable to tuberculosis or malaria, it is still difficult to diagnose and treat them. Beside the most prevalent and well-known fungal pathogens such as *Candida albicans* and *Aspergillus fumigatus*, a large number of new emerging pathogens have been described ([@B46]; [@B36]; [@B62]). In addition, the widespread use of antibiotics has probably influenced the balance between bacterial and fungal infections facilitating the occurrence of respiratory mycosis that are becoming resistant to antifungal drugs and difficult to treat ([@B14]; [@B87]; [@B7]).

Third, common links exist between fungi and diseases such as chronic respiratory diseases (CRD) through the immunogenic background of each individual. As part of the continuous host--pathogen--environment interaction from birth to death, fungi have been associated with asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), bronchiectasis at different levels (such as fungal isolation in a sputum sample, sensitization to *A. fumigatus* or to other fungi; [@B34]; [@B56]; [@B83]; [@B3]; [@B24]). The presence of fungi in respiratory tract also related to worse CRD outcome ([@B2]; [@B16]).

Despite the fact that knowledge of the mycobiome lags behind our understanding of the bacterial microbiome, specific mycobiota have been identified in pulmonary diseases as well as in oral, digestive, and skin diseases ([@B40]; [@B60]; [@B11]; [@B23]; [@B56]; [@B44]; [@B48]; [@B27]; [@B90]). Currently, the abundance of fungi in different body sites seems to be many degrees smaller than bacteriome as recently reported ([@B63]; [@B86]). For example, gut mycobiome has been evaluated at less than 0.1% in human feces upon the MetaHIT project ([@B49]). Since the development of the host immune system depends on its symbiotic relationship with the microbiome, the mycobiome may act as a cofactor in the lung inflammatory response ([@B63]). Therefore, it appears to be essential to understand more about respiratory mycobiome, and its potential interaction with other biomes in order to get a complete picture of the lung microbiome and to improve patient management by changing current paradigms of the disease.

In this review, we summarize the recent advances in characterizing the respiratory mycobiome of patients with CRD, and discuss the mycobiome's connections with other local microbial communities, as well as the relationships with the different biomes of other body sites. These studies suggest several outlooks for this emerging field which will certainly call for a renewal of our understanding of pulmonary diseases.

RESPIRATORY MYCOBIOME: FROM PROOF OF CONCEPT TO RATIONAL DATA
=============================================================

Conventional microbial methods such as cultures of respiratory samples are useful in diagnosing fungal infections and to isolating and phenotyping microorganisms. However, they have some limitations in identifying co-infections and dynamics of polymicrobial populations. These communities consist of bacteria, fungi, and viruses all potentially contributing to infection and inflammation ([@B60]; [@B10],[@B11]; [@B23]; [@B38]; [@B33]; [@B8]; [@B19]; [@B44]; [@B48]; [@B21]; [@B37]; [@B41]; [@B58]; [@B65]; [@B66]; [@B76]; [@B90]; [@B94]). In addition, the majority of fungal species are difficult to cultivate or uncultivable on usual culture media as well as new or unknown pathogens ([@B5]; [@B9]; [@B72]). In this context, deep-sequencing methods provide an indisputable possibility to identify all microbial species (including those difficult to culture) and to generate exhaustive microbial community data. Despite recent efforts to develop high-throughput methods targeting fungal ribosomal RNA genes to characterize fungal microbiota (recently summarized by [@B19], the published data have mainly explored the lung bacteriome. Only few studies have addressed respiratory community and diversity of fungi ([@B10],[@B11]; [@B23]; [@B44]; [@B93]; [@B90]) or viruses and phages ([@B91], [@B92]; [@B59]). But there is growing evidence to suggest the impact of viral infection on pulmonary exacerbation, and mold-related respiratory effects on CRD ([@B78], [@B77]; [@B50]; [@B55]).

Briefly, each lung microbiota (including mycobiota) has its own composition and evolution, which is unique and specific to each individual. It probably evolves according to the pulmonary disease and to the occurrence or not of an acute pulmonary exacerbation ([@B38]; [@B8]; [@B58]; [@B90]). As a consequence it is believed to play a role in the alteration of the lung function.

The lung mycobiome of healthy people are comprised various genus and species principally dominated by environment agents including *Aspergillus* species (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}; [@B11]; [@B93]; [@B63]; [@B86]). For example, in the study of [@B11], the most common taxa in healthy control groups are *Davidiellaceae*, *Cladosporium*, *Eurotium*, *Penicillium.* Similarly, the most abundant species of van Woerden's study ([@B93]) were environmental molds normally isolated from water, plant, or soil samples such as *Cladosporium cladosporioides* and *Eremothecium sinecaudum*.

![**Distribution of fungal classes (in % of relative abundance) in the sputum of healthy individuals (outer ring) and patients with CF (middle ring) and asthma (inner ring), based on published pyrosequencing investigations ([@B23]; [@B93]).** The percentages on the legend correspond to each class identified in healthy, CF, and asthma populations (from the outer to inner rings respectively). Reads that were not identified as class level are group at phylum levels (Ascomycota, Basidiomycota). Classes less than 0.1% are not represented in the rings; the class named "Fungi incertae sedis" refers to unclassified fungi.](fmicb-06-00089-g0001){#F1}

![**Venn diagram representing the comparison of the respiratory mycobiomes in healthy individuals, and patients with CF or asthma from published studies ([@B23]; [@B93]; [@B90]).** Shared genera are indicated in the overlap regions. The four most frequent species specifically isolated in each population are indicated in the non-overlap regions. Genera and species in red represent known opportunistic pathogens. In healthy people, *E. sinecaudum, Vanderwaltozyma polyspora*, and *Systenostrema alba* are Saccharomycetaceae and microsporidia isolated from soil and plants with no known clinical pathogenicity. *Cladosporium cladosporioides* has been described in cutaneous, subcutaneous, lung, and disseminated infections in immunocompromised patients. In the asthma population, *Psathyrella candolleana, Grifola sordulenta*, and *Termitomyces clypeatus* are environnemental Basidomycota. *Malassezia pachydermatis* is associated with atopic dermatitis. In CF patients, exclusively known opportunistic pathogens are the most frequent: *Aspergillus* species belonging to the Fumigata section are responsible for allergic disease (ABPA) as well as infection, while the pathogenicity of yeasts (*Candida* and *Malassezia*) is still a matter of debate in the context of CF. Among the shared fungal communities: *Eremothecium* is a filamentous fungus originally isolated from cotton; *Pseudotaeniolina* members are environmental fungi and occur only rarely in human hosts; *Rozella* is a widespread genus considered one of the earliest diverging lineages of fungi, isolated from the environment (marine); *Protomyces* is an Ascomycota phytopathogen; *Peniophorella* are soil Basidiomycota, of which few species are restricted to the northern hemisphere; *Dioszegia* are basidiomycetous yeasts found in a wide range of habitats; *Phlebiopsis* are saprotrophic fungi with a widespread distribution. *Cladosporium* species are becoming increasingly important opportunistic pathogens, especially in solid organ transplant recipients. *Malassezia* are members of the human skin flora which are associated with a wide spectrum of clinical manifestations from benign skin conditions (tinea versicolor) to fungemia in the immunocompromised host, or atopic dermatitis.](fmicb-06-00089-g0002){#F2}

The lung mycobiota of diseased subjects has been analyzed using deep-sequencing approaches for the first time in two studies conducted in 2012 ([@B11]; [@B23]). [@B23] have studied the sputum samples of CF patients while [@B11] investigated the bronchoalveolar lavage (BAL) and oropharyngeal wash (OW) samples of lung transplant patients suffering previously from different diseases such as CF, COPD, idiopathic pulmonary fibrosis, interstitial lung disease, and cardiovascular disease. In spite of some differences in the methodology of DNA extractions and data analysis between the two studies, the most common species or genera found in the lung mycobiome were: *C. albicans*, *Aspergillus* spp*.*, *Penicillium*, *Cryptococcus, Eurotium*, in which *Candida* species dominated (Figure [1](#F1){ref-type="fig"}). It was reported that more than 60% of the species or genera of the fungal communities identified using 454 FLX technology (Life Sciences) were not detected by cultures ([@B23]). These results were recently confirmed ([@B90]). [@B11] also applied the pyrosequencing method to characterize the airway microbiome in both the lower and upper respiratory tracts of lung transplant patients. It was shown that the respiratory microbial communities in lung transplant recipients differ in structure and composition from those of healthy subjects which were found to be similar to the oral microbiome described in another recent study ([@B40]). The lower respiratory tract of lung transplant subjects exhibited higher burdens of bacteria, and fungi were also detected. The richness and diversity of airway microbiota and mycobiota were markedly reduced in transplant subjects compared with control subjects, as well as in CF patients with decreased lung function and poor clinical status ([@B11]; [@B23]). In addition, macromycetes which had been found on the common trees in the forest in northern France were identified in sputum samples from several CF patients (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). This finding emphasized the significance of the exposure of the patients to the outdoor environment ([@B23]; [@B93]).

Interestingly, the *Malassezia* genus, which was detected as abundant taxa in the CF patients ([@B23]; [@B90]), was also found in patients with asthma but not in the control group ([@B93]; Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). This genus, which was recently identified as the dominant taxa on human core body and arms skin ([@B35]) is known to be associated with atopic dermatitidis. In addition, pyrosequencing studies revealed the presence of *Malassezia* species in oral cavity ([@B27]) and in sinonasal mucosa of patients with chronic rhinosinusitis ([@B17]). These results suggest that *Malassezia* species should have a greater interest in lung mycobiome research.

Up to now, lung mycobiome exhibited significant composition differences between patients with CRD and healthy individuals according to the limited studies based on next generation sequencing (NGS) technology ([@B11]; [@B23]; [@B93]; [@B90]). Moreover, the authors were also able to identify the changes in the lung mycobiota over different time and/or during therapies administered and correlate these changes with the clinical context. Although the sample size was rather small (eight sputum samples from four CF patients were studied), [@B23] suggested that the respiratory mycobiota plays a role in the development of CF lung pathology. *Candida* was the most commonly genus isolated in CF sputum samples, in particular *C. albicans* ([@B11]; [@B23]; [@B90]). *C. albicans* has been related to lung function decline in CF ([@B16]), even if its pathogenic role remained controversial. In addition, close interactions between fungi and bacteria in the lung microbiome of CRD patients have been proposed ([@B23]; [@B63]), in agreement with the recent ecological model of CF lungs, named the "climax-attack" community ([@B18]). In this model, climax communities are composed of persistent bacterial and fungal populations (for example *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Aspergillus* spp*.*, *Scedosporium* spp*.*) which colonize the airway during the stable periods. The attack communities are more virulent, usually composed of pathogenic microorganisms which are associated with pulmonary exacerbations such as *S. pneumoniae*, *H. influenza*, *Rhinovirus*, *Adenovirus*, etc.). Both attack and climax communities can coexist in CF patients' lungs and together contribute to the lung function decline. In this model, the climax community seems to be able to avoid the patients' immune responses and/or is more resistant to broad-spectrum antibiotic therapy. In contrast, the attack communities are expected to be more susceptible to antibiotics.

This model or other mathematical modeling together with metagenomic methods could help predict the effects of antimicrobial treatments on the lung microbiome, leading to a more effective use of antibiotic and/or antifungal drugs with different treatment regimens. On the whole, these findings provide novel approaches to addressing the relationship between microbial communities and pulmonary disease. It could help to assess lung infections by favoring the development of new therapeutic approaches and models. More investigations should be carried on this field to improve our knowledge of the role of the mycobiome in the lung microbiome and in chronic diseases, such as CRD.

RELATIONSHIPS BETWEEN THE LUNG AND GUT MICROBIOMES: FOCUS ON THE MYCOBIOME
==========================================================================

Despite limited research data, the concept of a relationship between the respiratory and gut microbiomes has recently been considered ([@B30]; [@B61]; [@B47]). The human gastrointestinal tract is colonized by a complex microbial community, which has been extensively studied during the last decade. The gastrointestinal microbiome is now considered an organ with an important role in digestive metabolism, in the development and homeostasis of host inflammatory immune responses. Dysbiosis of the gut microbiome has been associated with a variety of chronic diseases, such as inflammatory bowel disease, obesity, type 2 diabetes, and asthma ([@B85]; [@B47]; [@B54]). Furthermore, there is increasing evidence that the gastrointestinal mucosa is a predominant site of microbiome--host interactions and can contribute to the development of immune responses at distal mucosal sites.

Due to ethical considerations, the small size of samples, and/or technical problems, studies conducted on human beings to investigate the relationships between the gut and lung microbiomes are limited. However, animal models have been developed to test the influence of the gut microbiome on the lung microbiome and immunity. Using a mouse model of cefoperazone-induced gastrointestinal microbiome disruption, [@B70], [@B69]) demonstrated that the gastrointestinal dysbiosis was characterized by increased numbers of enteric bacteria and *C. albicans*. They also proved the impact of the gastrointestinal microbiome perturbation on immune responses in the lung. Only mice with altered gastrointestinal microbiota developed airway allergic responses to intranasal administration of ovalbumin, associated with significant increases in the levels of eosinophils, mast cells, interleukin (IL)-5 and IL-13, INFγ in the lungs, and IgE in serum. The eosinophilic nature of the inflammatory response was confirmed by lung histological analysis. The allergic response was also induced by intranasally delivered conidia of *A. fumigatus* using the same model to perturb the gut microbiome either in Balb/c or C57BL/6 mice. These studies demonstrated that the effects of gastrointestinal microbiome disruption were independent of the host genetic background, and that the airway allergic responses following this dysbiosis were independent of the nature of the allergen challenge but require IL-13 production in mouse models ([@B70], [@B69])*.* A more recent study ([@B4]) compared the bacterial communities isolated from BAL fluids, lung tissue biopsies, fecal samples, and vaginal lavage fluids of BALB/c mice. It has shown that the lung microbiota is distinct from the cecal microbiota but overlaps with the vaginal microbiota in this animal model. [@B4] recommended taking into account the lung microbiome and mycobiome when studying the pathogenesis of inflammatory lung diseases.

To date, only two clinical trials have been conducted in CRD populations to document the relationships between the gut microbiome and the lungs ([@B30]; [@B61]). Twenty-one children with CF and 24 healthy siblings were included in a cross-sectional study ([@B30]) in an effort to find any significant differences between the relative composition and temporal stability of the predominant fecal microbiome in CF patients and those in their healthy siblings, using culture and DGGE methods. Siblings were chosen as controls for patients with CF to avoid the effects of several factors that may influence the composition of the gastrointestinal microbiota, such as genetic background, age, and environmental factors. However, other factors, including antibiotic management in CF or the effect of daily diet, certainly differed since patients with CF are recommended to consume a high-fat diet to meet their energy needs. While enterobacterial counts were consistently higher in CF patients, no typical DGGE fingerprints were found from the cross-sectional study. The longitudinal study performed on two patient--sibling pairs exhibited a trend toward lower temporal stability and richness in the fecal microbiome of CF patients. Both cross-sectional and longitudinal studies provided primary evidence of a continuous state of intestinal dysbiosis in CF children compared to their siblings. Both the intrinsic characteristics of the disease (such as abnormal mucus secretions and pancreatic insufficiency) and the detrimental effects of intensive antimicrobial treatment courses most likely play key roles in this dysbiosis.

The second study, using the 16 rDNA gene pyrosequencing ([@B61]), investigated the respiratory and intestinal microbiota development in infants with CF followed from birth to 21 months. In observing the dominant genera, some similar bacteria were found in both gut and respiratory microbiota, such as *Veillonella* and *Streptococcus*. Bacterial diversity increased significantly over time in both the respiratory and intestinal tracts, and in which the respiratory microbiota increased more rapidly. A significant proportion of bacteria increasing in the gut were also increasing in the respiratory tract. Furthermore, changes in diet (such as breast-feeding or introduction of solid foods) also result in modified microbiomes, suggesting an authentic link between nutrition and the development of a microbial lung community ([@B61]). These data suggest that gut colonization patterns and nutritional factors play key roles in the development of the respiratory microbiome.

Changes in the intestinal microbiome also reflect changes in the oropharyngeal microbiome (including the mycobiome component), which may directly influence the respiratory microbiome and host immune response through microaspiration ([@B11]). The mycobiota of the oral cavity in healthy individuals has been well characterized ([@B40]; [@B27]). Among the 15 genera identified and composed of cultivable and non-cultivable species, *Candida* \[isolated from 75% of all study participants ([@B40])\], *Aspergillus*, *Fusarium*, and *Cryptococcus* were predominant. More recently, a high prevalence and abundance of the genus *Malassezia* was discovered by revising current practices in sequence-based taxonomy assignments ([@B27]). Like the oral bacterial microbiome, the oral mycobiome exhibited great variation within and between individuals that may influence the respiratory and intestinal mycobiomes in healthy individuals as well as in patients ([@B70], [@B69]; [@B1]; [@B40]; [@B55]; [@B27]; [@B67]).

Altogether, these studies support the concept that the indigenous microbiome and mycobiome of the gastrointestinal tract have a profound influence on the development and maintenance of the respiratory microbiome, as well as lung immunity and inflammation. Further studies targeting intestinal--respiratory microbiome interactions are likely to yield important insights into the dynamics and homeostasis of microbiomes, consequently yielding a better understanding of how intestinal dysbiosis may have notable functional consequences in the pathogenesis of CRD. These findings will represent opportunities for establishing the clinical relevance of early intervention in CRD with altered dietary or frequent antibiotic therapy that may contribute to the development of dysbiosis, or probiotic strategies that might change the colonization of the gut plus lung and thereby improve patients' outcomes. As this field advances over the next several years, we anticipate that studies using larger cohorts, control groups such as siblings, multicenter designs, and longitudinal sampling will add to our knowledge of the lung microbiome and mycobiome.

OUTLOOKS: THE RESPIRATORY MYCOBIOME OR A FORGOTTEN PLAYER THAT DESERVES OUR ATTENTION?
======================================================================================

Next generation sequencing technologies provide the opportunity to simultaneously analyze the microbial community (bacteria, viruses, and fungi) as a whole in an integrative research methodology without *a priori* knowledge of existing microorganisms, and consequently represent the most promising investigational strategy in the context of CRD (Figure [3](#F3){ref-type="fig"}). In the last half decade, interest in the human lung bacteriome and its role in developing CRD have increased substantially. As in the intestinal microbiome, bacteria are certainly the most represented microorganisms of the respiratory microbiome, but Archaea, viruses (including phages), and Eukaryota (including fungi) also formed part of this respiratory microbiome, and may reveal clinical significances especially when dysbiosis occurs. However, little to nothing is known about the role of fungi in establishing and maintaining a healthy respiratory ecosystem, or on the other hand in facilitating pulmonary diseases. In agreement with recent published data ([@B35]; [@B49]), fungi may play an important role in the stability of the human microbial community, thus affecting human health and disease.

![**Integrative research based on the lung mycobiome, virome, and bacteriome**.](fmicb-06-00089-g0003){#F3}

Given the significantly increased rate of allergic diseases such as asthma in the westernized countries, understanding the role of the lung microbiome especially the mycobiome will be of interest in coming decades. In addition, there is evidence that the fungal exposure is associated with asthma and chronic inflammatory pulmonary diseases ([@B78], [@B77]; [@B50]; [@B55]; [@B75]). Fungi are also potential pathogens of the lungs while they probably act as commensals in the gastrointestinal tract, making the mycobiome analysis valuable, or even higher in the respiratory tract.

When considering the respiratory microbiome as a complex and continuous polymicrobial ecosystem composed of viruses, bacteria, and fungi (as a parallel from Island biogeography recently proposed by [@B89]), these microorganisms may have mutual interferences. Unfortunately, their co-occurrence in the lung microbiome is poorly appreciated. To date, few studies underlined the impact of cross-kingdom synergy between bacteria and fungus in the respiratory tract and the sinonasal mucosa ([@B23]; [@B6]; [@B17]). The limited understanding of fungal--bacterial interactions and their function in respiratory diseases and healthy lungs results primarily from our incomplete knowledge of the respiratory mycobiome. Overall, information obtained from oral cavity and gastrointestinal ecosystems indicates that fungi influence bacterial behavior through different interactions (i.e., positive and negative influences between and among microbiome members; [@B29], [@B28]; [@B53]). As in other body sites, the interactions between fungi and bacteria may occur in the lungs at physical and chemical levels. The physical interactions are mainly represented by co-occurrence or co-exclusion phenomena, while the chemical interactions include metabolic needs, quorum-sensing exchanges, and the production of antimicrobial agents. Fungi and bacteria are able to generate biofilm structures which protect bacteria and/or fungi against desiccation, antibiotic diffusion, or immune cell attacks. It results in the development of strains that are multiresistant to antimicrobial agents and able to disseminate. Co-infection by these pathogens forming mixed communities has elevated virulence and resistance, and resilience properties that are significantly different from those of single-species communities (reviewed in [@B88]). Animal models have also shown the impact of cross-kingdom synergy between bacteria and fungi, supporting a potentially mutualistic partnership between *Candida* and *Streptococcus* ([@B81]; [@B26]; [@B64]; [@B95]).

By comparing cross-kingdom relationships associated with health and CRD using *in vitro* and *in vivo* studies, "omics" approaches will revolutionize the identification and characterization of fungal--bacterial interactions. Correlation network information already allowed authors to identify *Prevotella* species as growth co-partners of *Tannerella* sp. HOT286 and consequently to cultivate the uncultivated *Tannerella* bacteria in a co-culture system ([@B29]). Other authors revealed significant inter-bacteria associations at different body sites of healthy people ([@B32]). By exploring co-occurrence patterns of fungi and bacteria, [@B67] identified and explored antagonisms between *Candida* and *Pichia* yeasts in oral rinse samples. Furthermore, these bacterial--fungal interactions often have an important impact on the biology of the host metabolism and immunity as demonstrated in the gut microbiome (reviewed in [@B52]; [@B86]); they might also play a role in chronic pulmonary diseases and the pulmonary transplantation system, which emphasizes the need to define the respiratory mycobiome.

CONCLUSION AND FUTURE DIRECTIONS
================================

For a few decades, metagenomic research has focused on the bacterial microbiome; however, clinical and experimental studies have started to highlight a role for fungi in the human microbiome in general, and in the respiratory microbiome in particular. Such a polymicrobial community has emergent properties that cannot be inferred by studying its components separately. In this respect, the "omics" approaches will be significantly helpful in identifying and deciphering candidate fungal--bacterial interactions essential to maintaining a healthy respiratory microbiome, or on the other hand to facilitate CRD.

The rapid development of NGS technologies has opened up possibilities to better define in a novel way, the compositions and functions of the respiratory mycobiome and microbiome in homeostasis, during infection, and in the context of CRD. It is now essential to develop robust universal methodological strategies, and to implement large multicenter studies. In spite of recent methodological advances, the current metagenomic approaches used to study the mycobiome still have certain limitations. As proposed by [@B25], there are numerous pitfalls associated with the mycobiome that we need to challenge collectively. First, fungal cells are notoriously difficult to break open and might require chemical or mechanical lysis as a pre-extraction step ([@B13]; [@B39]; [@B43]; [@B74]; [@B27]; [@B42]). Another technical point in measuring fungi using a DNA based method, is to be able to distinguish the DNA of living microorganisms and that of dead ones. Several recent studies ([@B68]; [@B79]; [@B15]; [@B20]) demonstrated that a sample pre-treatment with propidium monoazide (a chemical molecule able to penetrate exclusively into cells with an intact membrane which are considered as viable cells) modified the bacterial community profiles obtained by NGS. The second challenge is to improve the taxonomic assignment quality by establishing an accurate updated fungal database. Since the internal transcribed spacer (ITS) regions of the rDNA are widely used for fungal species identification and recently formalized as universal DNA barcode markers for fungi ([@B23]; [@B82]), several projects have been conducted to develop fungal databases, such as ITSDB or UNITE for QIIME released^[3](#fn03){ref-type="fn"}^ ([@B25]) or ISHAM ITS Database^[4](#fn04){ref-type="fn"}^. The later ITS database was recently generated from quality controlled ITS sequences, which represent the actual sequence variation found in each species. Given that fungi represent the largest family of microorganisms with multiple names, another challenge is to prevent unnecessary nomenclatural flux, as recently proposed ([@B22]). In this context, the ISHAM ITS or UNITE databases represent a nice opportunity to create an accurate database with consensual nomenclature. Further advances in data generation and analysis are also required to minimize errors and misinterpretations, to make cross-studies and multicenter trials more feasible, and finally to link the bench and the clinic.

To understand the biological function of the respiratory mycobiome in host inflammatory lung responses, its implication in CRD progression, its role in local cross-kingdom microbial interactions, as well as in the cross-talk between the intestinal and lung microbiomes, future large-scale cross-sectional and longitudinal studies must be conducted to answer these questions raised. By analogy to the microbiota signatures recently proposed for assessing responses to dietary interventions in obese individuals ([@B57]) and for predicting future exacerbations in bronchiectasis ([@B80]), determining both specific mycobiota and microbiota respiratory signatures could be useful for prophylactic or therapeutic management in CRD. These microbiome and mycobiome signatures might also serve as specific biomarkers preceding the clinical manifestations of disease (CRD), which should be more sensitive than routine culture methods. They might then be an indicator for timely clinical intervention and successful disease management ([@B58]). The goal is to establish both the mycobiome and microbiome in the respiratory tract over time during a respiratory superinfection or an acute pulmonary exacerbation, in order to provide key elements (signatures, dysbiosis) for early diagnosis and appropriate preventive therapy of secondary infections. Longitudinal studies will help in analyzing fungal--bacterial interactions simultaneously during the CRD progression and therapy outcome. All these additional studies are needed to generate hypotheses that in vitro and animal models will explore.

By taking into account the total respiratory microbiome (that does not only consist of bacteria but also fungi, phages and viruses), these future studies will be dramatically instrumental in improving our knowledge of the pathogenesis of CRD and in developing innovative therapies.
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